Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Spero Therapeutics Inc Market Cap
The Spero Therapeutics Inc (SPRO) share price is expected to decrease by 100% over the next year. This is based on calculating the average 12-month share price estimate provided by 4 stock analysts who have covered SPRO. Price targets range from $ at the low end to $ at the high end. The current analyst consensus for SPRO is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 4 Wall Street analysts have assigned SPRO 3 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect Spero Therapeutics Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on SPRO. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of SPRO.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $7 | Reiterates | Aug 6, 2024 |
| Louise Chen Cantor Fitzgerald | Overweight | Reiterates | Aug 6, 2024 | |
| Ritu Baral TD Cowen | Buy | Upgrade | Aug 6, 2024 | |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $7 | Reiterates | May 16, 2024 |
| Louise Chen Cantor Fitzgerald | Overweight | Reiterates | Apr 4, 2024 | |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $7 | Reiterates | Mar 18, 2024 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $7 | Reiterates | Nov 14, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $7 | Reiterates | Sep 5, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $7 | Maintains | Aug 14, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $6 | Reiterates | Aug 1, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $6 | Reiterates | Jul 20, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $6 | Reiterates | Apr 10, 2023 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $6 | Maintains | Sep 26, 2022 |
| Josh Schimmer Evercore ISI Group | Outperform | $8 | Upgrade | Sep 23, 2022 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $7 | Maintains | Aug 15, 2022 |
| Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Maintains | May 23, 2022 |
Berenberg | Hold | Downgrade | May 20, 2022 | |
| Louise Chen Cantor Fitzgerald | Overweight | $5 | Maintains | May 17, 2022 |
| Josh Schimmer Evercore ISI Group | In-Line | $2 | Downgrade | May 4, 2022 |
Cowen & Co. | Market Perform | Downgrade | May 4, 2022 |
When did it IPO
2017
Staff Count
46
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Satyavrat Shukla C.F.A.
Market Cap
$74.6M
In 2023, SPRO generated $96.7M in revenue, which was a increase of 99.13% from the previous year. This can be seen as a signal that SPRO's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
